The information circular released by the national regulator updates the medicines that have their exports temporarily suspended, a list that is defined monthly to include medicines out of stock in the previous month and whose impact has been considered medium or high.

Compared to November, the list now published includes two fewer medicines, totalling 140 drug presentations from various categories and active substances, such as methylphenidate (psychostimulant), chlorpromazine (antipsychotic), propranolol (antihypertensive), the vaccine against meningococcus ( Nimenrix), Oxycodone (opioid analgesic) or the Japanese encephalitis vaccine (Ixiaro).

“This suspension aims to ensure the normalisation of the supply of critical medicines that were out of stock in October, as well as medicines that are being supplied under exceptional use authorisation”, says Infarmed in the document published its the website.

Infarmed monitors information on shortages, disruptions and sales cessation, to identify and avoid, in a timely manner, critical situations that could affect the availability of medicines.